Galluzzo Marco, D'Adamio Simone, Bianchi Luca, Talamonti Marina
a Division of Dermatology, Department of "Medicina dei Sistemi" , University of Rome "Tor Vergata" , Rome , Italy.
J Dermatolog Treat. 2019 Feb;30(1):40-44. doi: 10.1080/09546634.2018.1468066. Epub 2018 May 3.
Psoriasis tends to improve for approximately half of patients during pregnancy, but an equal number of patients report no change or worsening during this period, when lots of medications, like biologics, are not indicated. The aim of our study was to review data of patient that had been pregnant during ustekinumab treatment, analyzing data of our data set between September 2010 and February 2018. We found data of three patients that had been pregnant during ustekinumab treatment. All three patients successfully completed the pregnancy without complications. One of the three patients was pregnant even twice during treatment with ustekinumab, with also a successful birth of two perfectly healthy twins. Biologic agents approved for the treatment of moderate-to-severe psoriasis are currently classified as pregnancy category B, even if, particularly for ustekinumab, there are several case reports regarding exposure during pregnancy in humans related to a healthy pregnancy, both for women and children. Although further studies are required to find real indication of biological treatment in pregnant patients, according to our and to the reviewed experience, ustekinumab does not interfere with gestation.
银屑病在孕期约有半数患者病情趋于改善，但同样数量的患者报告在此期间病情无变化或加重，此时许多药物（如生物制剂）并不适用。我们研究的目的是回顾在使用乌司奴单抗治疗期间怀孕的患者数据，分析我们2010年9月至2018年2月数据集的数据。我们发现了3例在使用乌司奴单抗治疗期间怀孕的患者数据。所有3例患者均成功完成妊娠，无并发症发生。3例患者中有1例在使用乌司奴单抗治疗期间甚至怀孕了两次，还成功产下了两个完全健康的双胞胎。目前，被批准用于治疗中重度银屑病的生物制剂被归类为B类妊娠用药，即使，特别是对于乌司奴单抗，有几例关于人类孕期接触该药后母婴均健康妊娠的病例报告。尽管需要进一步研究以明确生物治疗在孕妇中的实际适应证，但根据我们的经验以及所回顾的经验，乌司奴单抗不会干扰妊娠。
